Skip to main content

GBIO

Stock
Health Care
Biotechnology

Performance overview

GBIO Price
Price Chart

Forward-looking statistics

Beta
1.37
Risk
92.44%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Company info

SectorHealth Care
IndustryBiotechnology
Employees175
Market cap$216.9M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth-0.9
Credit+9.4
Liquidity-0.5
Inflation-7.8
Commodities-0.9
Interest Rates-4.0

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-0.36
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.

Zacks Investment Research (May 7, 2025)
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (October 20, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free